The many faces of Interleukin-27 in liver diseases: from immune regulator to metabolic player.

Liver diseases, ranging from chronic liver disease (CLD) to acute liver injury (ALI), pose significant global health challenges. Metabolic dysfunction and inflammatory disorders are key to the progression of both CLD and ALI, suggesting that dual-targeting of metabolism and immune response may lead to better clinical performance for patients with liver disease. Interleukin-27 (IL-27) is a classic cytokine known for its immune-modulating role, with many ongoing clinical trials in the context of anti-tumoral therapy and inflammatory bowel disease. Our previous studies have revealed an unexpected role of IL-27 in promoting adipocyte thermogenesis and ameliorating role in systemic metabolism. This review outlines the involvement of the IL-27/IL-27R signaling pathway in hepatic metabolism and immunity, highlighting its potential as a therapeutic target for both CLD and ALI. Meanwhile, when serum IL-27 displays a disease-specific change in dynamic liver diseases, a summary and elaboration on its diagnostic potential are also carried out.